Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis

Cell Research

Volumn 13, Issue 4, 2003, Pages 239-249

  Dunne, Rebecca L ^a,b   Dunn, Linda A ^a   Upcroft, Peter ^a   O'Donoghue, Peter J ^b   Upcroft, Jacqueline A ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Drug resistance; Ferredoxin; Hydrogenase; Metronidazole; Pyruvate: ferredoxin oxidoreductase; Trichomonas vaginalis

Indexed keywords

MASTIGOPHORA (FLAGELLATES); PROTOZOA; TRICHOMONAS VAGINALIS;

ANTITRICHOMONAL AGENT; METRONIDAZOLE;

ANIMAL; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS;

ANIMALS; ANTITRICHOMONAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; METRONIDAZOLE; SEXUALLY TRANSMITTED DISEASES; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 1542572794     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7290169     Document Type: Article

References (82)

1. Peters W. Recent advances in antimalarial chemotherapy and drug resistance. Adv Parasitol 1974; 12:69-114.
2. Robinson SC. Trichomonal vaginitis resistant to metronidazole. Med Assoc J 1962; 86:665.
3. WHO. Global prevalence and incidence of selected curable sexually transmitted infections (informal publication). 1999.
4. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14:150-64.
5. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. 1998; 351:213-4.
6. Perez S, Fernandez-Verdugo A, Perez F, Vazquez F. Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis 2001; 28:115-6.
7. Lo M, Reid M, Brokenshire M. Resistance of Trichomonas vaginalis infections to metronidazole in Aukland sexual health clinics: report of two cases. N Z Med J 2002; 115:
8. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11:300-17.
9. Bui ETN, Johnson PJ. Identification and characterization of [Fe]-hydrogenases in the hydrogenosome of Trichomonas vaginalis. Mol Biochem Parasitol 1996; 76:305-10.
10. Voncken F, Boxma B, Tjaden J, Akhmanova A, Huynen M, Verbeek F, Tielens AG, Haferkamp I, Neuhaus HE, Vogels G, Veenhuis M, Hackstein JH. Multiple origins of hydrogenosomes: functional and phylogenetic evidence from the ADP/ATP carrier of the anaerobic chytrid Neocallimastix sp. Mol Microbiol 2002; 44:1441-54.
11. Ribeiro KC, Mariante RM, Coutinho LL, Benchimol M. Nucleus behavior during the closed mitosis of Tritrichomonas foetus. Biol Cell 2002; 94:289-301.
12. Skerk V, Schonwald S, Krhen I, et al. Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002; 19:471-4.
13. Price MA, Zimba D, Hoffman IF, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003; 30:516-22.
14. Szarka K, Temesvari P, Kerekes A, Tege A, Repkeny A. Neonatal pneumonia caused by Trichomonas vaginalis. Acta Microbiol Immunol Hung 2002; 49:15-9.
15. Temesvari P, Kerekes A, Tege A, Szarka K. Demonstration of Trichomonas vaginalis in tracheal aspirates in infants with early respiratory failure. J Matern Fetal Neonatal Med 2002; 11:347-9.
16. Saurina GR, McCormack WM. Trichomoniasis in pregnancy. Sex Transm Dis 1997; 24:361-2.
17. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998; 351:S5-7.
18. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistance or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34:1406-11.
19. Schwebke JR, Aira T, Jordan N, Jolly PE, Vermund SH. Sexually transmitted diseases in Ulaanbaatar, Mongolia. Int J STD AIDS. 1998; 9:354-8.
20. Bowden FJ, Paterson BA, Mein J, Savage J, Fairley CK, Garland SM, Tabrizi SN. Estimating the prevalence of Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and human papillomavirus infection in indigenous women in northern Australia. Sex Transm Infect 1999; 75:431-4.
21. Passey M, Mgone CS, Lupiwa S, Tiwara S, Lupiwa T, Alpers MP. Screening for sexually transmitted diseases in rural women in Papua New Guinea: are WHO therapeutic algorithms appropriate for case detection? Bull World Health Organ. 1998; 76:401-11.
22. Mgone CS, Lupiwa T, Yeka W. High prevalence of Neisseria gonorrhoeae and multiple sexually transmitted diseases among rural women in the Eastern Highlands Province of Papua New Guinea, detected by polymerase chain reaction. Sex Transm Dis 2002; 29:775-9.
23. Bowden FJ, Garnett GP. Why is Trichomonas vaginalis ignored? Sex Transm Infect. 1999; 75:372-4.
24. Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001; 7:927-32.
25. Durel P, Couture J, Bassoullet MT. The rapid detection of metronidazole in urine. Br J Vener Dis 1967; 43:111-3.
26. Spence MR, Harwell TS, Davies MC, Smith JL. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol 1997; 89:699-703.
27. Martinez V, Caumes E. Metronidazole. Ann Dermatol Venereol 2001; 128:903-9.
28. Upcroft JA, Upcroft P. Drug resistance in Giardia. Parasitol Today 1993; 9:187-90.
29. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999; 29:199-212.
30. Townson SM, Upcroft JA, Upcroft P. Characterisation and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis. Mol Biochem Parasitol 1996; 79:183-93.
31. Brown DM, Upcroft JA, Edwards MR, Upcroft P. Anaerobic bacterial metabolism in the ancient eukaryote Giardia duodenalis. Int J Parasitol 1998; 28:149-64.
32. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents 2002; 19:1-7.
33. Mler M. The Hydrogenosome. J Gen Microbiol 1993; 139:2879-89.
34. Upcroft JA, Upcroft P. Drug susceptibility testing of anaerobic protozoa. Antimicrob Agents Chemother 2001; 45:1810-4.
35. Diniz CG, Santos SG, Pestana A, Farias LM, Carvalho MAR. Chromosomal breakage in the B-fragilis group induced by metronidazole treatment. Anaerobe 2000; 6:149-53.
36. Land KM, Clemens DL, Johnson PJ. Loss of multiple hydrogenosomal proteins associated with organelle metabolism and high-level drug resistance in trichomonads. Exp Parasitol 2001; 97:102-10.
37. Tachezy J, Kulda J, Tomkova E. Aerobic Resistance of Trichomonas vaginalis to metronidazole induced in vitro. Parasitology 1993; 106:31-7.
38. Rasoloson D, Tomkova E, Cammack R, Kulda J, Tachezy J. Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology 2001; 123:45-56.
39. Tachezy J, Kulda J. Metronidazole resistance test in vitro in strains of Trichomonas vaginalis isolated from clinical material. 1. Test conditions. Cesk Epidemiol Mikrobiol Imunol 1991; 40:89-96.
40. Tachezy J, Kulda J. Metronidazole resistance test in vitro in strains of Trichomonas vaginalis isolated from clinical material. 2. Proposal for a standard tests. Cesk Epidemiol Mikrobiol Imunol 1991; 40:97-104.
41. Voolmann T, Boreham P. Metronidazole resistant Trichomonas vaginalis in Brisbane. Med J Aust 1993; 159:490.
42. Kulda J, Tachezy J, Cerkasovova A. In vitro induced anaerobic resistance to metronidazole in Trichomonas vaginalis J Eukaryot Microbiol 1993; 40:262-9.
43. Brown DM, Upcroft JA, Dodd HN, Chen N, Upcroft P. Alternative 2-keto acid oxidoreductase activities in Trichomonas vaginalis. Mol Biochem Parasitol 1999; 98:203-14.
44. Upcroft P. Drug resistance in Giardia: clinical versus laboratory isolates. Drug Resis Updates 1998; 1:166-8.
45. Liu SM, Brown DM, Oonoghue P, Upcroft P, Upcroft JA. Ferredoxin involvement in metronidazole resistance of Giardia duodenalis. Mol Biochem Parasitol 2000; 108:137-40.
46. Quon DVK, Doliveira CE, Johnson PJ. Reduced transcription of the ferredoxin gene in metronidazole- resistant Trichomonas vaginalis. Proc Natl Acad Sci USA 1992; 89:4402-6.
47. Mai X, Adams MW. Characterization of a fourth type of 2-keto acid-oxidizing enzyme from a hyperthermophilic archaeon: 2-ketoglutarate ferredoxin oxidoreductase from Thermococcus litoralis. J Bacteriol 1996; 178:5890-6.
48. Upcroft JA, Upcroft P. Keto-acid oxidoreductases in the anaerobic protozoa. J Eukaryot Microbiol. 1999; 46:447-9.
49. Land KM, Delgadillo MG, Johnson PJ. In vivo expression of ferredoxin in a drug resistant trichomonad increases metronidazole susceptibility. Mol Biochem Parasitol 2002; 121:153-7.
50. Rasoloson D, Vanacova S, Tomkova E, et al. Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology 2002; 148:2467-77.
51. Upcroft P. Multiple-drug resistance in the pathogenic protozoa. Acta Tropica 1994; 56:195-212.
52. Descoteaux S, Ayala P, Samuelson J, Orozco E. Increase in mRNA of multiple Eh pgp genes encoding P-glycoprotein homologues in emetine-resistant Entamoeba histolytica parasites. Gene 1995; 164:179-84.
53. Lar? D, Cayer S, Singh AK, Richard D, Papadopoulou B, Ouellette M. ABC proteins of Leishmania. J Bioenerg Biomembr 2001; 33:469-74.
54. Banuelos C, Orozco E, Gomez C, et al. Cellular location and function of the P-glycoproteins (EhPgps) in Entamoeba histolytica multidrug-resistant trophozoites. Microb Drug Resist 2002; 8:291-300.
55. Orozco E, Lopez C, Gomez C, et al. Multidrug resistance in the protozoan parasite Entamoeba histolytica. Parasitol Int 2002; 51:353-9.
56. Johnson PJ, Schuck BL, Delgadillo MG. Analysis of a single-domain P-glycoprotein- like gene in the early-diverging protist Trichomonas vaginalis. Mol Biochem Parasitol 1994; 66:127-37.
57. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995; 319:309-15.
58. Kaur J, Dey CS. Putative P-glycoprotein expression in arsenite-resistant Leishmania donovani down-regulated by verapamil. Biochem Biophys Res Commun. 2000; 271:615-9.
59. Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003; 47:1407-9.
60. Sobel JD, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001; 33:1341-6.
61. Lewis DA, Habgood L, White R, Barker KF, Murphy SM. Managing vaginal trichomoniasis resistant to high-dose metronidazole therapy. Int J STD AIDS 1997; 8:780-4.
62. Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: Report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 2000; 38:763-7.
63. Upcroft JA, Campbell RW, Benakli K, Upcroft P, Vanelle P. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents Chemother 1999; 43:73-6.
64. Poppe, WAJ. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol 2001; 96:119-20.
65. Watson PG, Pattman RS. Arsenical pessaries in the successful elimination of metronidazole-resistant Trichomonas vaginalis. Int J STD AIDS 1996; 7:296-7.
66. Chen MY, Smith NA, Fox EF, Bingham JS, Barlow D. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS 2001; 10:277-80.
67. Houang ET, Ahmet Z, Lawrence AG. Successful treatment of four patients with recalcitrant vaginal trichomoniasis with a combination of zinc sulfate douche and metronidazole therapy. Sex Transm Dis 1997; 24:116-9.
68. Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J Antimicrob Chemother 2000; 46:57-60.
69. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002; 18:95-7.
70. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 2002; 49:103-11.
71. Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. J Eukaryot Microbiol 2002; 49:201-8.
72. Camuzat-Dedenis B, Provot O, Cointeaux L, et al. Synthesis and in vitro Trichomonacidal activities of some new dialkylperoxides and 1, 2, 4-trioxanes. Eur J Med Chem 2001; 36:837-42.
73. Coombs GH, Mottram JC. Trifluoromethionine, a prodrug designed against methionine gamma-lyase-containing pathogens, has efficacy in vitro and in vivo against Trichomonas vaginalis. Antimicrob Agents Chemother 2001; 45:1743-5.
74. Delmas F, Di Giorgio C, Robin M, et al. In vitro activities of position 2 substitution-bearing 6-nitro- and 6-amino-benzothiazoles and their corresponding anthranilic acid derivatives against Leishmania infantum and Trichomonas vaginalis. Antimicrob Agents Chemother 2002; 46:2588-94.
75. Bouma MJ, Snowdon D, Fairlamb AH, Ackers JP. Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (deithyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. J Antimicrob Chem 1998; 42:817-20.
76. Malagoni M, Rossi T, Baggio A, et al. In vitro study of chemotherapeutic activity of sulphimidazole on some sensitive and metronidazole-resistant Trichomonas vaginalis strains. Pharmacol Res 2002; 46:469-72.
77. Lossick JG. Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis 1990; 12:S665-81.
78. Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis-an emerging problem. N Engl J Med 1999; 341:292-3.
79. Snipes LJ, Gamard, PM., Narcisi, EM, Beard, CB, Lehmann, T, Secor, WE. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol 2000; 38:3004-9.
80. Perez DG, Gomez C, Paz F, Orozco E. The multidrug-resistance phenotype of Entamoeba histolytica- transfected trophozoites with the EhPgp5 gene. Arch Med Res 2000; 31:S277-8.
81. Saurina G, DeMeo L, McCormack WM. Cure of metronidazole- and tinidazole-resistant trichomoniasis with use of high-dose oral and intravaginal tinidazole. Clin Infect Dis 1998; 26:1238-9.
82. Coelho DD. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med 1997; 73:397-8.